OmniAb (OABI) Share-based Compensation (2022 - 2026)
OmniAb (OABI) posted quarterly Share-based Compensation of $3.3 million for Q1 2026, down 19.4% year-over-year from $4.1 million in Q1 2025, and down 78.89% quarter-over-quarter from $15.8 million in Q4 2025.
OmniAb (OABI) Share-based Compensation (2022 - 2026) Analysis & Trends
OmniAb (OABI) has reported Share-based Compensation for 5 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 19.4% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $15.0 million (up 1093.39% YoY), while the FY2025 annual figure was $15.8 million, up 40474.36% from the prior year.
- Share-based Compensation declined to $3.3 million in Q1 2026 per OABI's latest filing, from $15.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $15.8 million in Q4 2025 and bottomed at -$10.1 million in Q3 2024.
- Historically, Share-based Compensation has averaged $1.9 million across 5 years, with a median of $3.2 million in 2022.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 56311.11% — and 2025, when it soared 1818.13%.
- OmniAb's Share-based Compensation stood at $10.1 million in 2022, then sank by 95.96% to $410000.0 in 2023, then plunged by 324.63% to -$921000.0 in 2024, then jumped by 1818.13% to $15.8 million in 2025, then tumbled by 78.89% to $3.3 million in 2026.
- Business Quant data shows OABI's Share-based Compensation at $3.3 million in Q1 2026, $15.8 million in Q4 2025, and -$8.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Mn |
| Jun 30, 2026 | 3.16 Mn |
| Mar 31, 2026 | 3.34 Mn |
| Mar 31, 2026 | 3.34 Mn |
| Dec 31, 2025 | 15.82 Mn |
| Dec 31, 2025 | 15.82 Mn |
| Sep 30, 2025 | -8.26 Mn |
| Sep 30, 2025 | -8.26 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Dec 31, 2024 | -921,000.00 |
| Dec 31, 2024 | -921,000.00 |
| Sep 30, 2024 | -10.12 Mn |
| Sep 30, 2024 | -10.12 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Jun 30, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.70 Mn |
| Mar 31, 2024 | 5.70 Mn |